XML 35 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
Collaboration and Other Agreements, Servier (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Dec. 31, 2014
Collaboration And Other Agreements [Line Items]              
Deferred revenue included in current liabilities   $ 3,783   $ 3,783   $ 5,866  
Deferred revenue included in long-term liabilities   9,794   $ 9,794   12,631  
Servier [Member] | Servier DART [Member]              
Collaboration And Other Agreements [Line Items]              
Collaboration or other agreement date       September 2012      
Non-refundable upfront payment $ 20,000            
Original period of development       29 months      
Expected period of development       75 months      
Option exercise fee             $ 15,000
Option exercise fee recognition period       82 months      
Offset to research and development costs under collaboration arrangement   1,000 $ 0 $ 2,100 $ 500    
Recognized revenue under agreement   800 $ 800 2,500 $ 2,600    
Deferred revenue   11,900   11,900   14,400  
Deferred revenue included in current liabilities   3,300   3,300   3,300  
Deferred revenue included in long-term liabilities   8,600   8,600   $ 11,100  
Servier [Member] | Servier DART [Member] | Maximum [Member]              
Collaboration And Other Agreements [Line Items]              
Potential license fee   65,000   65,000      
Potential clinical milestone payments   98,000   98,000      
Potential regulatory milestone payments under agreement   300,000   300,000      
Potential sales milestone payments under agreement   630,000   630,000      
Additional Potential Milestone Payments Receivable Upon New Drug Application Acceptance   $ 5,000   $ 5,000